Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balstilimab vs Chemotherapy in Recurrent Cervical Cancer (BRAVA)
NCT04943627Phase 3Withdrawn
- Sponsor
- Agenus Inc.
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of balstilimab in Cervical Cancer (CC) (2 arms), sponsored by Agenus Inc. Primary endpoint: Overall Survival up to 36 months. Planned start Aug 2021; status: withdrawn.
02
Drugs
balstilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04943627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943627.